Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma

NCT00490451 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00490451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00490451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
February 28, 2010
Enrollment
101 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, soft tissue